A Diagnostics & Imaging Week

Nanosys (Palo Alto, California) and Bruker Daltonics (Billerica, Massachusetts) have entered into a broad R&D collaboration and distribution agreement for Nanosys’ nanotechnology-enabled matrix-free target plates for use primarily with Bruker’s FLEX-series of laser desorption ionization (LDI) time-of-flight (TOF) mass spectrometers. These Nanosys plates are known as Capture and Analyze (CA) NALDI chips.

NALDI chips are designed to enable significant sensitivity, throughput and ease-of-use benefits for the analysis of small molecules.

Potential applications areas include chemistry and molecular biology research, molecular diagnostics and molecular imaging research, pharma/biotech and other industrial research and analysis, as well as many applied fields, such as food analysis, environmental analysis and toxicology.

The companies will collaborate closely on R&D related to the NALDI chips, as well as on applications and assay development. Nanosys will manufacture and exclusively supply NALDI chips for Bruker LDI-TOF mass spectrometers, while Bruker Daltonics will market and distribute the chips worldwide.

Financial details of the agreement were not disclosed.

Nanosys develops nanotechnology-enabled products utilizing high-performance inorganic nanostructures.

Bruker Daltonics is a developer of life science tools based on mass spectrometry, and it also offers a broad line of chemical, biological, radiological and nuclear detection products for homeland security.

CDW Healthcare (Vernon Hills, Illinois), a provider of technology products and services to healthcare, said it has signed an agreement with Barco (Kortrijk, Belgium) to build and distribute integrated medical imaging solutions based upon Barco medical displays, Barco advanced visualization software solutions and workstations from HP and IBM.

The companies said this product package provides advanced visualization and analysis of CT, MR and PET images and will be available for the first time to a Barco distribution partner through CDW Healthcare.

The integrated package bundles Barco’s Coronis and Nio lines of diagnostic imaging displays, Barco’s visualization software for 3-D viewing of CT, MR and PET images and workstations from HP and IBM. Barco’s visualization software enables diagnosticians to manipulate medical images — such as a cranial CT scan — along its x, y and z axis, providing them with a fully three-dimensional view of the subject. Healthcare IT staff can readily customize the workstation configuration to the specific use and specifications that they require.

In addition to the imaging package, CDW Healthcare also will offer Barco’s Nio and Coronis LCD display lines. These display systems range from two to five megapixels and display images in full color and grayscale.

Premier Purchasing Partners (Charlotte, North Carolina) reported new agreements for its core laboratory products portfolio, including agreements for capital equipment, supplies, consumables and service for integrated platforms, immunochemistry, hematology, hemostasis and urinalysis products and services.

Agreements for integrated platforms, which incorporates chemistry, immunochemistry and lab automation, have been awarded to Beckman Coulter (Brea, California); Dade Behring (Deerfield, Illinois); and Siemens Medical Solutions Diagnostics (Tarrytown, New York).

Agreements for immunochemistry have been awarded to Abbott Laboratories (Abbott Park, Illinois); Beckman Coulter; Dade Behring; and Siemens Medical Solutions Diagnostics.

Agreements for hematology have been awarded to Abbott Laboratories; Beckman Coulter; and Sysmex America (Mundelein, Illinois)

Agreements for hemostasis have been awarded to Beckman Coulter; Dade Behring; and Diagnostica Stago (Parsippany, New Jersey).

Agreements for urinalysis have been awarded to Siemens Medical Solutions Diagnostics and Iris Diagnostics (Chatsworth, California).

All agreements are effective April 1 and are available for 36 months, with the exception of the agreements for urinalysis which are available for 40 months.